Apremilast in psoriasis – a prospective real‐world study

ConclusionsDespite differences between real‐world and trial patients, apremilast is safe and effective for the treatment of skin psoriasis in the daily practice. Up to 40% of patients will reach PASI50 or higher, but only few patients will reach PASI90. Bodyweight might affect drug efficacy.

Source: Journal of the European Academy of Dermatology and Venereology - October 12, 2017 Category: Dermatology Authors: I. Vujic, R. Herman, M. Sanlorenzo, C. Posch, B. Monshi, K. Rappersberger, L. Richter Tags: Original Article Source Type: research